NEW YORK, Aug. 2 /PRNewswire/ -- HealthShares(TM) Inc., an investment company with a series of 20 underlying fund portfolios, today announced it has been informed by Standard & Poor's, the...
HOUSTON, May 9 /PRNewswire-FirstCall/ -- Tanox, Inc. (NASDAQ:TNOX) today reported financial results for the first quarter ended March 31, 2007. Total revenues for the first quarter of 2007 were...
HOUSTON, March 15 /PRNewswire-FirstCall/ -- Tanox, Inc. (NASDAQ:TNOX) today reported financial results for the fourth quarter and full year 2006. Fourth Quarter 2006 Financial Overview Total...
SOUTH SAN FRANCISCO, Calif. and HOUSTON, Jan. 29 /PRNewswire-FirstCall/ -- Genentech, Inc. (NYSE:DNA) and Tanox, Inc. (NASDAQ:TNOX) today announced that they have received a Request for...
HOUSTON, Jan. 15 /PRNewswire-FirstCall/ -- Tanox, Inc. (NASDAQ:TNOX) (the "Company") announced today that its stockholders have voted to adopt the merger agreement providing for the merger of...
SOUTH SAN FRANCISCO, Calif. and HOUSTON, Nov. 9 /PRNewswire-FirstCall/ -- Genentech, Inc. (NYSE:DNA) and Tanox, Inc. (NASDAQ:TNOX) today announced plans for Genentech to acquire Tanox, a...
Total Revenue Increases 84% Year Over Year HOUSTON, Nov. 2 /PRNewswire-FirstCall/ -- Tanox, Inc. (NASDAQ:TNOX) today reported financial results for the third quarter ended Sept. 30, 2006. Total...
HOUSTON, Oct. 25 /PRNewswire-FirstCall/ -- Tanox, Inc. (NASDAQ:TNOX) has begun dosing a Phase 1 clinical trial of TNX-650, a humanized monoclonal antibody being evaluated as a potential...
HOUSTON, Oct. 24 /PRNewswire-FirstCall/ -- Tanox, Inc. (NASDAQ:TNOX) will report its 2006 third quarter financial results Nov. 2, 2006. The announcement will be made prior to market open, with...
HOUSTON, Sept. 14 /PRNewswire-FirstCall/ -- Tanox, Inc. (NASDAQ:TNOX) will be among the featured companies presenting at the UBS Global Life Sciences Conference Sept. 25-28 in New York...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관